Abstract
The Swiss contract pharmaceutical services firm Siegfried has acquired a 95% stake in DiNAMIQS, a small Swiss firm that specializes in the manufacture of viral vectors for cell and gene therapies, from DiNAQOR. The deal marks a first step into biologics for Siegfried, which markets integrated drug substance and drug product services. Siegfried wants to expand DiNAMIQS’s operations to commercial scale by building a plant at DiNAMIQS’s current site in the Zurich-Schlieren area. Siegfried’s total investment will be in the “mid double-digit million Swiss Francs,” it says in a press release . The plant is expected to be operational by 2025. Siegfried has the option of acquiring the remaining 5% of DiNAMIQS from DiNAQOR in 5 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
